MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: HTG Molecular Diagnostics, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

HTG Molecular Diagnostics Adds Three Executive Team Members - HTG Molecular Diagnostics, a provider of products for gene expression profiling for clinical research, companion diagnostic and prognostic applications in oncology recently added three professionals to its executive team - HTGmolecular.com
HTG Molecular Diagnostics Adds Three Executive Team Members

 

NewswireToday - /newswire/ - Tucson, AZ, United States, 2012/02/14 - HTG Molecular Diagnostics, a provider of products for gene expression profiling for clinical research, companion diagnostic and prognostic applications in oncology recently added three professionals to its executive team - HTGmolecular.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

HTG Molecular, a privately-held, Tucson-based provider of molecular-technology solutions, added three industry-renown professionals to its executive team: Shaun McMeans, Vice President of Finance, Administration and Chief Financial Officer; Timothy J Holtzer, Ph.D., M.A., Vice President of Clinical Diagnostic Development; and Sam Rua, Vice President of Regulatory Affairs and Quality Systems.

Shaun McMeans, Vice President of Finance, Administration and Chief Financial Officer, joined HTG Molecular in February, 2012, and leads the organization’s finance and administration groups. Immediately prior to joining HTG Molecular, Mr. McMeans served as the CFO for Securaplane Technologies in Tucson. McMeans’ extensive experience includes positions as CFO of The Long Companies, interim CFO with Fluoresco and Inter-Fab, and as the CFO and COO of LXU Healthcare, Inc. Mr. McMeans moved to Tucson in 2000 from Lancaster, Pennsylvania where he enjoyed a twelve-year career in finance at Burnham Corporation. Mr McMeans earned a B.S. in Accounting from Penn State University.

Timothy J. Holtzer, Ph.D., M.A., Vice President of Clinical Diagnostic Development, joined HTG Molecular in January, 2012, and leads clinical diagnostic development. Prior to joining HTG Molecular, Dr. Holtzer dedicated over 25 years of his career to diagnostic development in large and small diagnostic companies in the US and Canada. Dr. Holtzer directed diagnostic teams at DiagnoCure, and Centocor, Cancer Genetics as well as leading cross-functional teams at Abbott Laboratories and the Whitehead Institute. Dr Holtzer received his B.A. from the University of Minnesota, his M.A. from Mankato State University and his Ph.D. from the University of Illinois at Chicago.

Sam Rua, Vice President of Regulatory Affairs and Quality Systems, joined HTG Molecular in November, 2011, and directs the quality systems organization and global regulatory initiatives. Prior to joining HTG, Mr. Rua served in a variety of quality and regulatory roles with increasing responsibilities, most recently with Ventana Medical Systems, a member of the Roche Diagnostics Group. Mr. Rua has successfully led applications for PMA approvals and clearances for multiple IVD and companion diagnostic tests. Mr. Rua’s career includes positions as VP of Global Regulatory and Clinical Affairs at Beckman Coulter, and Executive Director of Quality and Regulatory at Third Wave Technologies, Inc. (now Hologic), where he led the regulatory and clinical strategies for the Invader® UGT1A1 test and the Invader® HPV test. Mr. Rua received his B.S. in Microbiology from the University of Arizona.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics (htgmolecular.com) is a privately-held, Tucson-based company providing products for gene expression profiling, miRNA, siRNA and mRNA measurement for clinical research, companion diagnostic and prognostic applications in oncology. The company’s qNPA molecular technology platform is well-suited for reliably detecting changes in gene expression levels especially from formalin-fixed, paraffin-embedded (FFPE) tissue.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: HTG Molecular Diagnostics, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


HTG Molecular Diagnostics Adds Three Executive Team Members

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Kimberly Schmitz - SpurPublicRelations.com 
520-247-5778 Kimberly[.]spurpublicrelations.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any HTG Molecular Diagnostics, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From HTG Molecular Diagnostics, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan
BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research
Global Bio-Based Chemicals Market Projected to Grow At a CAGR of 16.67% by 2027 Finds Inkwood Research
The Global Animal Nutrition Market Projected to Grow At a CAGR of 5.94% by 2027 Finds Inkwood Research
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-small Cell Lung Cancer
BTG to Invest in Chinese Medical Isotope Diagnosis and Treatment Company Chengdu New Radiomedicine Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)